From the Research
Daily Dosage of Kanuka Honey for Treating Inflammation in MCAS
There is limited research on the daily dosage of Kanuka honey for treating inflammation in Mast Cell Activation Syndrome (MCAS). However, some studies suggest that honey, in general, has anti-inflammatory properties:
- A study published in 2021 1 found that honey contains flavonoids and phenolic acids, which have antioxidant and anti-inflammatory properties.
- A study published in 2012 2 found that Kanuka honey exhibited potent, dose-dependent reduction of human neutrophil superoxide production in vitro, indicating its anti-inflammatory activity.
- Another study published in 2016 3 found that Kanuka essential oil had anti-inflammatory effects by lowering tumor necrosis factor-α released after lipopolysaccharide stimulation in THP-1 cells.
MCAS Treatment
MCAS is a complex condition that requires a personalized treatment approach:
- A study published in 2022 4 emphasized the importance of diagnosing the variant of MCAS precisely and taking into account accompanying conditions and comorbidities when establishing a management plan.
- A study published in 2016 5 discussed pharmacological treatment options for MCAD, including agents targeting MC proliferation and mediator release. However, none of these studies provide specific guidance on the daily dosage of Kanuka honey for treating inflammation in MCAS. Further research is needed to establish the clinical efficacy of Kanuka honey in this context.